BMS’ Breyanzi and Amgen’s Blincyto will now be available to patients in England with certain types of blood cancer.

My annual scan showed no cancer recurrence, but revealed some minor issues related to aging and potential fibroids, requiring ...

Genmab (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved EPKINLY or epcoritamab, for the treatment of ...

NICE's initial guidance on Breyanzi concluded it was not a cost-effective option for patients, but the agency said this ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued Final Draft Guidance ...

Galapagos shifts to CAR-T therapy with GLPG5101, targeting pivotal trials by 2026. Click here to find out why I rate GLPG ...

We recently published a list of 10 Stocks Kick Off Trading Week With Losses. In this article, we are going to take a look at where Tempus AI, Inc. (NASDAQ:TEM) stands against other stocks kick off ...

Tempus AI (TEM) stock surged 13.4% on Thursday, hitting a new 52-week high of $86. The upside came after the health ...

A case study on how DelveInsight supported a client with a focused CAR-TCR Summit coverage plan to gain exclusive insights into CAR-T therapies for B-cell malignancies.New York, USA, Feb. 21, 2025 (GL ...